Hydroxychloroquine In Coronavirus Disease 2019 Patients: What Still Needs To Be Known About The Kinetics

G Martin-Blondel,S Ruiz, M Murris,S Faguer, V Duhalde,F Eyvrard, J Izopet,J M Mansuy, Y Rolland,K Delavigne, R Guimbaud, G Pugnet,J M Conil,B Georges,P Delobel,V Minville, S Silva Sifontes,D Concordet,P Gandia

CLINICAL INFECTIOUS DISEASES（2020）

引用 12|浏览222

暂无评分

摘要

Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations.

查看译文

关键词

COVID-19, hydroxychloroquine, drug monitoring, population pharmacokinetic modeling, dosage regimens

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要